

SUPPLEMENTARY INFORMATION

Impact of Delta and Vaccination on SARS-CoV2 transmission risk: Lessons for Emerging Breakthrough infections

Kalpna Sriraman, Ambreen Shaikh, Smriti Vaswani, Tejal Mestry, Grishma Patel, Shalini Sakthivel, Vikas Oswal, Pratibha Kadam, Kayzad Nilgiriwala, Daksha Shah, Mangala Gomare, Nerges Mistry

Supplementary Table 1 – Comparison of patient clinical parameters, COVID-19 symptom characteristics stratified based on vaccination status

Descriptions	Overall	Cs-D1	Cs-D2	Cx-D2	Unvaccinated
Clinical parameters					
Lymphocytes (%) (median + IQR)	33 (26.7-39.1)	34 (29.5 - 39.5)	29 (17-38)	34.5 (27.5 - 44)	32 (26-35)
Platelets (thou/ μ L) (median + IQR)	253 (187-300)	286 (232 -314)	240 (177-288)	236 (174- 307)	271 (179-509)
Hemoglobin (g/dL) (median + IQR)	13.3 (11.7 -14.2)	13.5 (12.5 - 14)	13.4 (11.3 - 15.3)	13.4 (12.2 -14.1)	12.5 (11.6-13.6)
CRP (mg\L) (median + IQR)	7.8 (2.9 - 16)	7.75 (2.8 - 11)	10.2 (5.3- 20.3)	6.7 (2.6-18.1)	8.3 (1.71-13.1)
LDH (U/L) (median + IQR)	246 (173- 295)	209 (165 - 264)	256 (168- 280)	277 (189 -333)	NA
Symptoms at Enrolment					
Fever	44	16	11	13	4
Cough	55	18	13	17	6
Sore throat	25	10	5	7	1
Loss of Smell/Taste	51	13	14	17	7
Headache	15	4	5	3	3
Body ache/Weakness	27	10	4	9	3
Chills	7	1	1	4	1
Gastric Problems	5	0	2	1	2
Shortness of Breath	3	0	0	2	1
Cold	25	7	10	6	1
Symptoms at Follow-up					
Fever	2	0	0	2	0
Cough	37	12	7	14	4
Sore throat	4	0	1	1	2
Loss of Smell/Taste	37	8	11	15	3
Headache	6	1	1	4	0
Body ache/Weakness	6	1	0	5	0
Chills	1	0	0	1	0
Gastric Problems	6	1	1	4	0
Shortness of Breath	1	0	0	0	1
Cold	12	4	2	5	1
Types of Comorbidities					
Diabetes	14	0	9	4	1
Hypertension	9	0	5	2	2
Cardiovascular Disease	9	0	2	6	1
Others	14	4	2	6	2

All values are represented as the number of patients unless specified otherwise. Cs-D1 – One dose of Covishield, Cs-D2 - Two doses of Covishield and Cx-D2 – Two doses of COVAXIN; Ct value – cycle Threshold value; IQR – interquartile range. Cx-D1 group was not included in the analysis due to low patient number (N=2)

Supplementary Table 2 – Viral strain of the sequenced patient samples

SARS-CoV-2 strain	Number of Patients
Delta	66
Delta Derivative (AY.120)	9

Supplementary Table 3 – Comparison between Mask High Viral Emitters and Not High Emitters*

Descriptions	High Emitters (N=37)	Not High Emitters* (N=55)	p-value	Adjusted p-value (Multivariate Analysis)	
Age (median + IQR)	40 (30-50)	41 (31-50)	0.761	0.115	
Gender					
Male	23	28	0.392		
Female	14	27			
Vaccine Status					
Cs-D1	7	19	>0.999	0.475	
Cs-D2	14	14	0.32	0.678	
Cx-D1	1	1	>0.999	0.228	
Cx-D2	11	13	0.49	0.893	
Unvaccinated	4	9			
Swab Ct Value at Diagnosis (median + IQR)	20 (16-24)	21 (17-25.7)	0.305	0.091	
Swab Viral Load at Recruitment (log Value) (median + IQR)	6.5 (5.6 – 7.5)	4.4 (2.7-5.6)	<0.0001	0.027 Adjusted for Age, Vaccine status, Number of comorbidities, Swab Ct value at Diagnosis, Cough as a symptom, Day's post symptom onset and effect of days post symptom onset and comorbidities on viral load	
Number of Symptoms	4 (2-5)	3 (2-4)	0.341		
Type of Symptoms					
Fever	17	28	0.675	0.334	
High	3	4	>0.999		
Mild	15	25	0.673		
Cough	27	28	0.038		
Sore Throat	12	13	0.473		
Loss of Smell and Taste	16	35	0.058		
Shortness of Breath	2	1	0.562		
Cold	12	13	0.473		
Number of comorbidities	1 (0-1)	0	0.001		0.976
Type of comorbidities					
Diabetes	9	5	0.073		
Hypertension	6	4	0.193		
CVD	4	1	0.153		
Others	8	6	0.236		
Duration between last dose of vaccination to infection (median + IQR)	47 (21-87)	58 (21-77)	0.707		
Antivirals taken	23	32	0.829		
Days post symptom onset (median + IQR)	3 (3-4)	4 (3-5)	0.023	0.566	
Sampling score (median + IQR)	7 (6-7.75)	6 (5-8)	0.217		


*Includes moderate, low, and zero emitters. All values are represented as the number of patients unless specified otherwise. IQR-Interquartile range

Supplementary Table 4 – Comparison Between Single infection and Multiple infection households

Description	Single infection households (N=22)	Multiple infection households (N=67)	p-value	Adjusted p-value (Multivariate Analysis)	
Age (median + IQR)	39 (30-50)	40 (31-49)	0.764	0.432	
Gender					
Male	10	39	0.331	Adjusted for Age, No of Symptoms, Fever as a symptom, Days between the last dose of vaccination to infection and adjusted for the effect of Days between the last dose of vaccination to infection in CS-D2 patients	
Female	12	28			
Vaccine status					
Cs-D1	7	18	0.065		
Cs-D2	2	26	0.018		
Cx-D2	6	17	0.119		
Unvaccinated	7	4			
Days between last dose of vaccination to infection (median + IQR)	58 (26-77)	63 (37-87)	0.021		0.227
Number of symptoms	3 (1-4)	3 (2-5)	0.236		0.401
Types of symptoms					0.259
Fever	9	36	0.221		
Cough	12	17	0.67		
Sore throat	6	37	>0.999		
Gastric problems	11	4	>0.999		
Cold	4	20	0.408		
Viral load in mask (Log Value, median + IQR)	2.2 (1.6-3.7)	2.8 (1.6-4.1)	0.371	0.786	
Viral load in Swab (Log Value, median + IQR)	4.4 (2.-6.1)	5.6 (4.5-6.6)	0.011		
Ct value at diagnosis (median + IQR)	21 (17-24)	20 (16.5-24)	0.337		
Family type					
Nuclear	8	34	0.326		
Joint	14	33			
Days post symptom onset (median + IQR)	4 (3-5)	4 (3-5)	0.495		
Antivirals Taken	12	43	0.455		


Single infection Household – Only study patient infected with SARS-CoV-2, multiple infection Household – Study patient + Household member/s infected with SARS-CoV-2, IQR-Interquartile range

Supplementary Figure 1



Supplementary Figure 1: Scatter plot depicting the NPS Ct value on X-axis and mask viral load on Y-axis **1A**- at Enrolment and **1B** – Follow up

Supplementary Figure 2



Supplementary Figure 2 – Probit Analysis – The graphs describe the probability of being mask positive (2A), swab positive (2B) or a high emitter (2C) on any day after the symptom onset of SARS-CoV-2 infection as calculated by Probit (MedCalc software, 20.019). The red lines highlight the probability of being mask (2A), swab (2B) positive or high emitter (2C) tenth day from symptom onset.